Back to search

Article

New prognostic factors in chronic myeloid leukaemia

2010-01-01

Abstract excerpt

The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of patients with chronic myeloid leukaemia (CML) but about 15% of patients do not achieve complete cytogenetic responses (CCyR) (primary resistance) and a further 15-20% of those who do achieve CCyR eventually lose their response (secondary resistance). The best characterised mechanism of resistance is the expansion o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1d799e1f-b0bc-5e8c-a649-ae9f6f6bef99
DOI
10.25560/5626
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
New prognostic factors in chronic myeloid leukaemiaDOI 10.25560/5626
Prognostic factors in chronic myeloid leukaemia therapySemantic proximity
Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemiaSemantic proximity
Investigation of molecular heterogeneity and new prognostic biomarkers in chronic myeloid leukaemiaSemantic proximity
Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.Semantic proximity
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLSemantic proximity
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.Semantic proximity
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.Semantic proximity
Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.